Partnering
EBI’s management team collaborates closely with its Scientific Advisory Board and external advisors to leverage their expertise into the full development of EBI’s product pipeline. Moreover, EBI is always interested to investigate partnering opportunities with life sciences companies, academic institutes, and investors to leverage the potential of EBI’s compounds into solutions for urgent unmet medical needs.
Opportunities for partnering
EBI is a clinical stage company developing novel polypeptides to address postoperative complications, hemodynamic instability as well as systemic inflammation disorders. We are exploring the full therapeutic range for our compounds with our first product focused on postoperative complications. By teaming up with other life sciences companies, academic institutes, and investors, we are in a position to fully develop the huge potential of these human-derived peptides. We are always interested in working with partners with whom we can optimize our product portfolio and accelerate our clinical development. You are most welcome to contact us to discuss business and partnering opportunities.
External Advisors
EBI collaborates closely with external advisors in their specific fields of expertise. These include:
Radboud university medical center
Radboud University Medical Centre is an academic hospital in the Netherlands. Researchers at the Radboud University Medical Center focus on today’s scientific health challenges as well as observing emerging diseases of the future. Their work is centered on people and their quality of life. Radboud University Medical Centre is the site for the current clinical development efforts of EBI.
CR2O
As a contract research organization (CRO), CR2O is the lead manager of the Phase III clinical development program. CR2O’s experience in drug development and full clinical trial services integrated with Good Laboratory Practice (GLP), Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) compliance and expertise ensure efficient development program, high quality data collection, management and reporting and hence accelerate the development of EA-230, the Company’s lead product.